FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Staten Christopher
2. Date of Event Requiring Statement (MM/DD/YYYY)
7/30/2021 

3. Issuer Name and Ticker or Trading Symbol

AERIE PHARMACEUTICALS INC [AERI]
(Last)        (First)        (Middle)

C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Interim CFO /
(Street)

DURHAM, NC 27703      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 22587 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)  (1)11/5/2025 Common Stock 59500 $24.70 D  
Stock Option (right to buy)  (1)2/1/2027 Common Stock 14650 $43.90 D  
Stock Option (right to buy)  (2)1/30/2028 Common Stock 13835 $56.25 D  
Stock Option (right to buy)  (3)1/30/2029 Common Stock 12516 $46.86 D  
Stock Option (right to buy)  (4)8/14/2029 Common Stock 12516 $23.97 D  
Stock Option (right to buy)  (5)8/14/2030 Common Stock 12516 $12.71 D  
Stock Option (right to buy)  (6)7/1/2031 Common Stock 12516 $16.22 D  

Explanation of Responses:
(1) These options are fully vested as of the date hereof.
(2) These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of January 30, 2018.
(3) These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of January 30, 2019.
(4) These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of August 14, 2019.
(5) These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of August 14, 2020.
(6) These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of July 1, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Staten Christopher
C/O AERIE PHARMACEUTICALS, INC.
4301 EMPEROR BLVD., SUITE 400
DURHAM, NC 27703


Interim CFO

Signatures
/s/ John LaRocca, Attorney-in-Fact for Christopher Staten8/5/2021
**Signature of Reporting PersonDate

Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Aerie Pharmaceuticals Charts.
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Aerie Pharmaceuticals Charts.